Earnings Summary

4d Molecular Therapeutics Inc’s revenue jumped 47.53% since last year same period to $0.24Mn in the Q2 2023. On a quarterly growth basis, 4d Molecular Therapeutics Inc has generated -19.8% fall in its revenue since last 3-months.

4d Molecular Therapeutics Inc’s net profit fell -5.45% since last year same period to $-29.62Mn in the Q2 2023. On a quarterly growth basis, 4d Molecular Therapeutics Inc has generated -8.65% fall in its net profits since last 3-months.

4d Molecular Therapeutics Inc’s net profit margin jumped 28.53% since last year same period to -12391.63% in the Q2 2023. On a quarterly growth basis, 4d Molecular Therapeutics Inc has generated -35.47% fall in its net profit margins since last 3-months.

4d Molecular Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.79 - a 13.19% jump from last quarter’s estimates.

4d Molecular Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.79.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. 4d Molecular Therapeutics Inc’s return on assets (ROA) stands at -0.22.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. 4d Molecular Therapeutics Inc’s return on equity (ROE) stands at -0.37.